On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > BUSINESS
BUSINESS
- Takeda Obtains Japan Rights to Exelixis’ Cancer Drug
February 1, 2017
- Astellas Gets Rights to US Biotech’s Ruptured Eardrum Med
February 1, 2017
- Major Products Face Impending Listing of Generics, though Patents Remain for Some
February 1, 2017
- Biogen to Keep Its Focus on High Unmet Needs, Win-Win Partnerships: CEO
January 31, 2017
- Latuda OK’ed in US for Adolescent Schizophrenia
January 31, 2017
- Mochida Filed Enbrel Biosimilar in Japan in October-December
January 31, 2017
- Linzess Delivers Positive Japan PIII Data in Chronic Constipation: Astellas
January 31, 2017
- Nippon Chemiphar, Nagase Medicals Win Elplat Patent Suit
January 30, 2017
- Mitsubishi Tanabe, Biogen Terminate MS Licensing Deal
January 30, 2017
- SBI to Initiate UK PII Study of 5-ALA for Prevention of Postoperative Cardiac Output Reduction
January 30, 2017
- Shionogi to Seek Expansion of Pediatric Indication for Sublingual Allergen Immunotherapy Tablet Actair
January 30, 2017
- Chugai to Shuffle Sales Organization to Cater to Community-Based Care
January 27, 2017
- Mochida Will Groom Lialda into Flagship Quickly: President
January 27, 2017
- Daiichi Sankyo Espha to Launch Micardis AG, Will Actively Handle Competitors’ Products
January 27, 2017
- Sumitomo Dainippon Completes Tolero Acquisition
January 27, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in OS as Liver Cancer 1st Line Treatment
January 27, 2017
- Pfizer Adjusts Shipments for Tazopipe, Voluntarily Recalls Metformin Generics
January 27, 2017
- Biogen Japan to Make New Start as MS Powerhouse after Hemophilia Spin-off
January 25, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Takara Bio to Initiate PI/II Trial of Gene Therapy for Synovial Sarcoma
January 25, 2017
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…